Latest kidney diseases Stories

FierceMedicalDevices Names Vessix Vascular One Of 'Fierce 15' Medical Device And Diagnostic Companies Of 2012

2012-10-02 06:26:20

LAGUNA HILLS, Calif., Oct. 2, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. Vessix was chosen as one of the Fierce 15 based, in part, on the innovation, creativity and promise of the Vessix V2 Renal...

Chronic Kidney Disease A Warning Sign Independent Of Hypertension Or Diabetes

2012-09-27 00:03:48

Two new studies from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium found that the presence of chronic kidney disease itself can be a strong indicator of the risk of death and end-stage renal disease (ESRD) even in patients without hypertension or diabetes. Both hypertension and diabetes are common conditions with chronic kidney disease with hypertension being the most prevalent. The studies were released online in advance of...

Children With Kidney Disease Have Abnormal Carotid Arteries

2012-09-20 16:48:42

Striking findings highlight need for aggressive monitoring, early treatment to prevent later heart attacks, strokes A federally funded study led by researchers at Johns Hopkins Children's Center has found that children with mild to moderate kidney disease have abnormally thick neck arteries, a condition known as carotid atherosclerosis, usually seen in older adults with a long history of elevated cholesterol and untreated hypertension. The findings — published online ahead of print on...

Cytochroma Initiates Phase 3 Study of CTAP101 Capsules in Chronic Kidney Disease Patients

2012-09-20 02:29:59

MARKHAM, ON, Sept. 20, 2012 /PRNewswire/ - Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules ("CTAP101 Capsules") in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The newly initiated trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of CTAP101 Capsules as a new treatment for SHPT...

Questcor to Conduct Conference Call to Discuss Reimbursement Process

2012-09-19 14:21:40

ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT. The call can be accessed in the following ways: By webcast: At Questcor's investor relations website: http://ir.questcor.com/. By telephone:...

OxThera Raises Capital for Further Clinical Development of Oxabact(R)

2012-09-19 02:29:50

STOCKHOLM, September 19, 2012 /PRNewswire/ -- OxThera AB has successfully raised MSEK 39 in a rights issue. The proceeds from the financing will enable OxThera to complete a new clinical study to confirm the positive effects of treatment with Oxabact(R) previously seen in patients with Primary Hyperoxaluria, a debilitating medical condition for which there is no effective treatment today. "We appreciate the continued support from our shareholders, including HealthCap,...

Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America

2012-09-10 10:26:19

SUNNYVALE, Calif. and SEATTLE, Sept. 10, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today presented positive data from its randomized, double-blind Phase 2a clinical study of CLP1001. In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo. Data from the Phase 2a study were presented by Barry...

NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy

2012-09-06 02:32:15

LAWRENCE, Mass., Sept. 6, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding its Proposed Rule for the Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System for 2013. NxStage's comments call for CMS to correct the current insufficient and inequitable payments for home hemodialysis...

Nick Cannon Steps Up for New Gig -- Host of the National Kidney Foundation's Kidney Walk

2012-08-29 06:24:02

NEW YORK, Aug. 29, 2012 /PRNewswire/ -- Award winning actor, comedian and host of NBC-TV's top rated "America's Got Talent," will soon shine the spotlight on the body's least known but most hardworking organ--the kidney. Nick Cannon, who never gave his own kidneys a second thought, was hospitalized last winter for acute kidney injury and diagnosed with lupus nephritis. His condition has stabilized and he's now stepping out in support of the National Kidney Foundation's Kidney Walk to...

NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients

2012-08-29 02:26:06

LAWRENCE, Mass., Aug. 29, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that the American Association of Kidney Patients (AAKP) has honored NxStage System One(TM) patient Brian Hess with the Samuel J. Orenstein Award. The award is presented each year to the AAKP member who consistently provides extraordinary service in helping the organization achieve its goals to educate and improve the health...